SCHEMBL1709010

SCHEMBL1709010

O=C(c1cnc2ccccc2c1)N1CCC(B(O)O)CC1

nearest known ligand 0.57

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
DPP4 P27487 2/20 0.57
CCR3 P51677 1/20 0.53
CAPN1 P07384 1/20 0.52
MGAM O43451 1/20 0.50
CNR1 P21554 1/20 0.47
CNR2 P34972 1/20 0.47
FASN P49327 1/20 0.47
NPC1 O15118 1/20 0.46
RAB9A P51151 1/20 0.46
CHRNB2 P17787 1/20 0.46
CHRNA7 P36544 1/20 0.46
CHRNA4 P43681 1/20 0.46
HTR2B P41595 1/20 0.46
KDM2B Q8NHM5 1/20 0.46
ACACB O00763 1/20 0.45
ACACA Q13085 1/20 0.45
HPGDS O60760 1/20 0.44
SYK P43405 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16002871 0.81 DPP4 (0.54) DPP4CCR3CAPN1MGAMCNR1
SCHEMBL30791185 0.81 CCR3 (0.66) DPP4CCR3
SCHEMBL13889101 0.81 CCR3 (0.64) DPP4CCR3
SCHEMBL13826660 0.80 DPP4 (0.54) DPP4CCR3CAPN1MGAMCNR1
SCHEMBL28178640 0.79 SMN1; SMN2 (0.63) DPP4CCR3MGAMFASNNPC1
SCHEMBL7722174 0.79 MKNK1 (0.59) DPP4CCR3CAPN1MGAMCNR1
SCHEMBL9635312 0.79 MGLL (0.58) DPP4CCR3CAPN1MGAMKDM2B
SCHEMBL30791180 0.79 CCR3 (0.65) DPP4CCR3CAPN1NPC1ACACB
SCHEMBL6210205 0.78 HSD11B1 (0.65)
SCHEMBL7722304 0.77 DPP4 (0.54) DPP4CCR3CAPN1MGAMCNR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8802119-B2 Inhibitors of fatty acid amide hydrolase INFINITY PHARMACEUTICALS, INC. (US) 2014-08-12 US disclosed
US-8802119-B2 Inhibitors of fatty acid amide hydrolase INFINITY PHARMACEUTICALS, INC. (US) 2014-08-12 US disclosed
US-8541581-B2 Inhibitors of fatty acid amide hydrolase INFINITY PHARMACEUTICALS, INC. (US) 2013-09-24 US disclosed
US-8541581-B2 Inhibitors of fatty acid amide hydrolase INFINITY PHARMACEUTICALS, INC. (US) 2013-09-24 US disclosed
US-20120088738-A1 INHIBITORS OF FATTY ACID AMIDE HYDROLASE INFINITY PHARMACEUTICALS ,INC (US) 2012-04-12 US disclosed
US-20120088738-A1 INHIBITORS OF FATTY ACID AMIDE HYDROLASE INFINITY PHARMACEUTICALS ,INC (US) 2012-04-12 US disclosed
WO-2010118159-A1 INHIBITORS OF FATTY ACID AMIDE HYDROLASE INFINITY PHARMACEUTICALS, INC. (US) 2010-10-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120088738-A1 INHIBITORS OF FATTY ACID AMIDE HYDROLASE FAAH, FAAH2, CES1 DPP4 1110/4885CCR3 1054/4885CAPN1 797/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.